TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00028769
Drug: nilutamide
Normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00028769
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001730
Drug: Thyrogen
Normalized name: Thyrogen
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01271517
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
Study: NCT01271517
Drug: Detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
Study: NCT00009217
Drug: Haloperidol-Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
Study: NCT00009217
Drug: Haloperidol-Placebo
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
Study: NCT00238212
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01844388
Drug: carboxymethylcellulose based eye drop formula
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
Study: NCT01072240
Drug: rituximab [Mabthera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by physician
Study: NCT01844388
Drug: carboxymethylcellulose sodium based eye drop solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
Study: NCT00139074
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral variable dose
Study: NCT00139074
Drug: sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01500772
Drug: Alisporivir
Normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALV 200 mg soft gel capsules administered orally
Study: NCT01500772
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study: NCT01500772
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study: NCT00176774
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
Study: NCT00176774
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
Study: NCT00176774
Drug: Tetrathiomolybdate
Normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
Study: NCT00964496
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study: NCT02171507
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02305030
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01180192
Drug: oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: either 8 L/minute O2 via face mask for 2 hours
Study: NCT03185156
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
Study: NCT00096967
Drug: Avastin (bevacizumab)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01442519
Drug: electromotive mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
Study: NCT02976337
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active drug infusion
Study: NCT01255423
Drug: Diclofenac sodium topical gel 1%
Normalized name: DICLOFENAC SODIUM 10 mg in 1 g TOPICAL GEL [Diclofenac Sodium Topical Gel 1%]
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium topical gel 1%, 4 times daily
Study: NCT00988598
Drug: PF-04447943
Normalized name: PF-04447943
DrugBank: PF-04447943 (DB11953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of PF-04447943 orally every 12 hours for 7 days
Study: NCT00231777
Drug: Comparator: ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single administration of 4 mg ondansetron by IV immediately prior to surgery
Study: NCT01780324
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention - intraurethral lidocaine
Study: NCT04347902
Drug: Intravenous Lipid Emulsion
Normalized name: propofol lipid emulsion
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various types of intravenous lipids
Study: NCT00160186
Drug: Pancreatin
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
Study: NCT01517347
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT06316908
Drug: Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants assigned to the unilateral neurolytic celiac plexus block group underwent a minimally invasive procedure where a solution of absolute alcohol was injected unilaterally into the celiac plexus under image guidance. The procedure was performed by an experienced interventional pain specialist. Prior to the injection, local anesthesia was administered to minimize discomfort. Once positioned correctly, a needle was inserted into the designated area, and a small amount of absolute alcohol was injected to disrupt the neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide long-term pain relief for participants suffering from chronic abdominal pain.
Study: NCT06316908
Drug: Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants allocated to the bilateral neurolytic celiac plexus block group underwent a similar minimally invasive procedure as described above, with the exception that the injection of absolute alcohol was administered bilaterally into the celiac plexus. The procedure was performed by an experienced interventional pain specialist under image guidance, with local anesthesia administered prior to the injection to ensure patient comfort. Following correct needle placement, absolute alcohol was injected into both sides of the celiac plexus to disrupt neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide comparable or potentially enhanced long-term pain relief compared to the unilateral approach, with the additional benefit of targeting both sides of the celiac plexus.
Study: NCT04730999
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
Study: NCT04730999
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
Study: NCT04447625
Drug: Oral antibiotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
Study: NCT04730999
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
Study: NCT02601157
Drug: 3-months DAPT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
Study: NCT04730999
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit.
Study: NCT00015990
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT02675309
Drug: MT-8554
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04447625
Drug: Intrauterine antibiotic infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Study: NCT02254304
Drug: Rebif
Normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
Study: NCT02601157
Drug: 1-year DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
Study: NCT02726620
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic drug used to maintain general anesthesia
Study: NCT02726620
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic drug used to maintain general anesthesia
Study: NCT02726620
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic drug used to maintain general anesthesia
Study: NCT02726620
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic drug used to maintain general anesthesia
Study: NCT02726620
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Isoproterenol
Normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drugs used to treat intraoperative hypotension
Study: NCT02726620
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Sodium Chloride 0.9%
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02726620
Drug: Hydroxyethyl starch solutions
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02726620
Drug: Albumin solutions
Normalized name: albumin human, USP Injection [Albuminar]
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02726620
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Procaine
Normalized name: Procaine
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Chloroprocaine
Normalized name: Chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02726620
Drug: Articaine
Normalized name: Articaine
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT04347252
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
Study: NCT00673218
Drug: Xolair
Normalized name: Xolair
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 to 375 mg is administered SC every 2 or 4 weeks
Study: NCT00645190
Drug: Galantamine HBr
Normalized name: galantamine HBr
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02058706
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02058706
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03395899
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-L1 antibody
Study: NCT03395899
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Highly selective small-molecule inhibitor of MEK1 and MEK2
Study: NCT03395899
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt
Study: NCT03395899
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Highly specific humanized monoclonal antibody that targets VEGF
Study: NCT00003815
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003815
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00369733
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
Study: NCT00003815
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00360386
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00003815
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003815
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03188159
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
Study: NCT00006053
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00057863
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00057863
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00367939
Drug: valsartan + amlodipine
Normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02462148
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used in nerve block mixture
Study: NCT02462148
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in nerve block mixture
Study: NCT03248271
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin